ATRA clinical trials
ATRA is named as an intervention in 14 current clinical trials in our China, France, Spain, Italy, Israel, Canada, Ireland, Germany, Netherlands, Belgium, Sweden, Denmark, Czechia, Portugal, USA and Australia registers. 7 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Peking University People's Hospital (3). The most-studied condition is Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA.
Patient leaflets for ATRA
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of ATRA
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with ATRA
26 conditionsAll 26 conditions
| Condition (as registered) | Trials |
|---|---|
| Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | 2 |
| Persistent Isolated Chemotherapy-Induced Thrombocytopenia | 2 |
| Chemotherapy-Induced Thrombocytopenia | 2 |
| Acute Promyelocytic Leukemia | 1 |
| Acute Promyelocytic Leukemia (APL) | 1 |
| Acute Promyelocytic Leukaemia | 1 |
| Acute Promyelocytic Leukemia With PML-RARA | 1 |
| Dup15q Syndrome | 1 |
| Autism Spectrum Disorder | 1 |
| Therapy | 1 |
| All-trans Retinoic Acid | 1 |
| Gastrointestinal Neoplasms | 1 |
| Pancreatic Cancer | 1 |
| Rhabdomyosarcoma | 1 |
| Triple-negative Breast Cancer | 1 |
| AML | 1 |
| APL | 1 |
| Gynecologic Cancers | 1 |
| Ovarian Cancer | 1 |
| Immune Thrombocytopenia | 1 |
| AML, Adult | 1 |
| Oropharynx Cancer | 1 |
| Larynx Cancer | 1 |
| Hypopharynx Cancer | 1 |
| Primary Head and Neck Tumor | 1 |
| Advanced Pancreatic Ductal Adenocarcinoma | 1 |
Sponsors
lead sponsor per trialBy country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about ATRA trials
How many clinical trials are testing ATRA?
14 current trials in our China, France, Spain, Italy, Israel, Canada, Ireland, Germany, Netherlands, Belgium, Sweden, Denmark, Czechia, Portugal, USA and Australia registers name ATRA as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are ATRA trials recruiting patients?
Yes. 7 of the 14 trials are recruiting: 4 with sites in China, 3 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 1 with sites in Israel, 1 with sites in Ireland, 1 with sites in Germany, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Sweden, 1 with sites in Denmark, 1 with sites in Czechia, 1 with sites in Portugal and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors ATRA clinical trials?
Peking University People's Hospital (3), Associazione Italiana Ematologia Oncologia Pediatrica (1), Quetzal Therapeutics (1) and Second Affiliated Hospital, Zhejiang University, School of Medicine (1), among 12 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there ATRA clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ATRA works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ATRA works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ATRA (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.